Key facts
- PharmaBio’s last known valuation is $54.7M (Apr 2023).
- It has raised $34.5M; the latest was Later Stage VC in Jul 2025.
- Notable investors include Nippon Venture Capital, The University of Tokyo Edge Capital, Gogin Capital, Alfresa Holdings, LINK-J — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for PharmaBio
- ·The full record, as it builds
Funding rounds
No funding rounds for PharmaBio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About PharmaBio
Developer of regenerative medical products designed to produce improved-quality final medical products and drugs from living cells and tissues. The company's products contribute to medical and social progress and challenge the process of development of new drugs, enabling customers to have cell and tissue-based medicines.
- Sector
- Healthcare
- HQ
- Tokyo, Japan
- Founded
- 1978
- Employees
- 11
- Website
- pharmabio.co.jp/
- Ownership
- Privately Held (backing)
PharmaBio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in PharmaBio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on PharmaBio in its N-PORT filings yet. We sweep new filings monthly.